MapLight Therapeutics, Inc. Stock-Based Compensation
MapLight Therapeutics, Inc. (MPLT) reported Stock-Based Compensation of $18.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- MapLight Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $8.63M, a 5728.38% increase year-over-year.
- MapLight Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $9.64M, a 4445.28% increase year-over-year.
- MapLight Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $35.52M, a 16498.60% increase year-over-year.
- MapLight Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $125.00K.
- MapLight Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $36.01M, a 3233.89% increase from fiscal 2024.
- MapLight Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.08M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $18.26M 10-Q · filed 2026-08-13 | $53.78M derived: sum of 3 quarters · filed 2026-08-13 | $53.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.64M 10-Q · filed 2026-05-14 | $45.16M derived: sum of 2 quarters · filed 2026-05-14 | $45.28M derived: sum of 3 quarters · filed 2026-05-14 | $45.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $35.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $35.65M derived: sum of 2 quarters · filed 2026-03-26 | $35.79M derived: sum of 3 quarters · filed 2026-08-13 | $36.01M 10-K · filed 2026-03-26 |
| 2025-09-30 | $125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-04 | $273.00K derived: sum of 2 quarters · filed 2026-08-13 | $485.00K 10-Q · filed 2025-12-04 | $699.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $360.00K 10-Q · filed 2026-08-13 | $574.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $212.00K 10-Q · filed 2026-05-14 | $426.00K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.08M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $866.00K 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |